CD274 and cancer: The association of tremelimumab (anti CTLA-4) to durvalumab (anti PD-L1) did not add significant advantages in chemo-refractory GC and GJE cancers [155], whereas the combination of nivolumab and ipilimumab demonstrated more favorable safety and efficacy profiles [156].